30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
- Poster presentation
- Open Access
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy
Journal for ImmunoTherapy of Cancer volume 3, Article number: P53 (2015)
Strategies that enhance the function of T cells are critical for immunotherapy.
Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1.
We showed that the gene knockout of PD-1 by electroporation of plasmids encoding sgRNA and Cas9 was technically feasible. The disruption of PD-1 resulted in significant reduction of PD-1 expression but didn't affect the viability of primary human T cells. Cellular immune response of the gene modified T cells was characterized by up-regulated IFN-γ production and enhanced cytotoxicity.
These results suggest that we have established an approach for efficient checkpoint inhibitor disruption, providing a new strategy for targeting checkpoint inhibitors to improve the efficacy of T cell based adoptive therapies.
Topalian SL, Hodi S, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012, 366: 2443-2454.
Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, et al: Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014, 21 (3): 262-271.
Lloyd A, Vickery ON, Laugel B: Beyond the antigen receptor: editing the genome of T cells for cancer adoptive cellular therapies. Front Immunol. 2013, 4: 221-
Li W, Teng F, Li T, Zhou Q: Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol. 2013, 31 (8): 684-686.
Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al: Generation of gene- modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013, 23: 720-723.
Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al: Generation of gene-modified Cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014, 156 (4): 1-8.
Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al: Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014, 11 (4): 399-402.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2014, 366 (26): 2443-2454.
Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, et al: siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T cell effector functions. Gene Therapy. 2012, 19 (10): 959-966.
Chicaybam L, Sodre AL, Curzio BA, Bonamino MH: An efficient low cost method for gene transfer to T lymphocytes. PLOS One. 2013, 8: e60298-
The authors thank the entire Huang Lab and Liu Lab for their support and advice. This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81172281, 81000980, 81220108023, 81172094).
About this article
Cite this article
Su, S., Liu, B. & Zou, Z. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy. j. immunotherapy cancer 3, P53 (2015). https://doi.org/10.1186/2051-1426-3-S2-P53
- Public Health
- Immune Response
- Cellular Immune Response
- Gene Knockout
- Mediate Approach